Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars M Wagner

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Pediatric Blood & Cancer|January 6, 2010
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium studyLars M Wagner, John P Perentesis, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumorsLars M Wagner, Kristine R Crews, Lisa C Iacono, et al.
Cancer Research|September 5, 2002
Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patientsLars M Wagner, Sylvie M Guichard, Rebecca A Burger, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2013
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupRobert E Goldsby, Timothy M Fan, Doojduen Villaluna, et al.
Pediatric Blood & Cancer|May 10, 2020
Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer FoundationJavier E Oesterheld, Damon R Reed, Bhuvana A Setty, et al.
Pediatric Blood & Cancer|September 15, 2017
Consensus and controversies regarding the treatment of rhabdomyosarcomaScott C Borinstein, Diana Steppan, Masanori Hayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium studyMaryam Fouladi, Clinton F Stewart, James Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium studyLars M Wagner, Judith G Villablanca, Clinton F Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2014
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium ReportMaryam Fouladi, John P Perentesis, Lars M Wagner, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 15, 2007
Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trialsElke Will, Jeff Bailey, Todd Schuesler, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Pediatric Blood & Cancer|January 6, 2010
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium studyLars M Wagner, John P Perentesis, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumorsLars M Wagner, Kristine R Crews, Lisa C Iacono, et al.
Cancer Research|September 5, 2002
Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patientsLars M Wagner, Sylvie M Guichard, Rebecca A Burger, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2013
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupRobert E Goldsby, Timothy M Fan, Doojduen Villaluna, et al.
Pediatric Blood & Cancer|May 10, 2020
Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer FoundationJavier E Oesterheld, Damon R Reed, Bhuvana A Setty, et al.
Pediatric Blood & Cancer|September 15, 2017
Consensus and controversies regarding the treatment of rhabdomyosarcomaScott C Borinstein, Diana Steppan, Masanori Hayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium studyMaryam Fouladi, Clinton F Stewart, James Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium studyLars M Wagner, Judith G Villablanca, Clinton F Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2014
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium ReportMaryam Fouladi, John P Perentesis, Lars M Wagner, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 15, 2007
Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trialsElke Will, Jeff Bailey, Todd Schuesler, et al.
Pageof 5